United Kingdom bans puberty blockers indefinitely

In December 2024, the British government announced that the ban on prescribing puberty blockers to minors with gender dysphoria would remain in place indefinitely. The ban will be reviewed in 2027.

What the ban entails

The ban applies to the prescribing and supplying of puberty blockers to young people under eighteen with gender dysphoria, including by private providers and doctors based abroad. The medications remain available for other conditions, such as precocious puberty.

How it came about

NHS England had already stopped routinely prescribing puberty blockers in March 2024. Shortly after the Cass Review, the government introduced a temporary emergency ban on private providers. An independent expert committee subsequently advised that prescribing posed an unacceptable safety risk as long as better safeguards were lacking.

Only within research

Treatment with puberty blockers is now possible in the United Kingdom only as part of scientific research. A clinical trial has been set up for this purpose.

From emergency measure to permanent ban

The ban was introduced in stages. In May 2024, shortly before the British election, the Conservative health secretary imposed an emergency ban that took effect in June. It closed a loophole: young people who could no longer obtain blockers through the NHS were turning to private clinics and providers abroad that issued prescriptions online. After the election, the new Labour government kept the ban in place. An advocacy group challenged the measure in court, but in July 2024 the High Court ruled that the minister had acted lawfully. The ban was extended several times and also applies in Northern Ireland.

The experts' advice

The government asked the Commission on Human Medicines for advice. This is the independent committee that advises the British government on the safety of medicines. The committee concluded that prescribing puberty blockers to minors with gender dysphoria posed an unacceptable safety risk at that time. It pointed not only to the medication itself, but also to the circumstances in which it was prescribed: without a thorough assessment, without support, and without monitoring the consequences.

Those already receiving treatment

Young people who were already using puberty blockers when the ban was introduced were allowed to continue treatment. The ban does not apply to sex hormones. In England, these could be prescribed from the age of sixteen, under strict conditions and following assessment by a national team. On March 9, 2026, NHS England suspended that policy: since then, young people under eighteen have no longer been starting hormones, and those already receiving them are being reassessed. The final policy will follow a consultation that ran until June 7, 2026. More information is available in the article on cross-sex hormones for minors at NHS England.

The research

One of the recommendations of the Cass Review was to provide puberty blockers only in a research setting, so that reliable data on their effectiveness and risks could finally become available. A study has been set up under the leadership of King's College London. In August 2026, the High Court dismissed a case seeking to stop the trial; see the news report on the trial involving 226 children. There is considerable debate about its design: some believe it is irresponsible to expose children to a treatment whose benefits have not been established, while others believe it is irresponsible to withhold the treatment from them.

Significance

The ban is notable because it was introduced and maintained by two successive governments of different political persuasions. In the United Kingdom, the treatment of minors is therefore no longer an issue on which the major parties disagree. This distinguishes the country from the United States, where the issue is divided along party lines; see the ruling in the Skrmetti case.

The United Kingdom thus went further than the Scandinavian countries, which had restricted the treatment to exceptional cases but had not banned it. A comparison of these policy shifts can be found on transtijd.nl in the article on Sweden, Finland and the United Kingdom. Outside Europe, Singapore decided in May 2026 to introduce a ban on hormonal and surgical treatment for gender dysphoria in minors. More information can be found on the page about gender care in the United Kingdom.